Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3175)	12/6/1997 10:49:00 PM
From: Izzy	Respond to of 6136

John, I think you meant to say bullshit lie! His statements are very inflammatory and he must have some subversive agenda. You know, he's not even worth replying to. Sorry I even gave him any response at all. He has no credibility whatsoever.

To: JOHN W. who wrote (3175)	12/8/1997 1:53:00 AM
From: George T. Santamaria	Read Replies (1) \| Respond to of 6136

<In a recent tech letter, I read that Glaxo was not impressed with the 70% response to VX-478 nad was planning to withdraw from the collaboration.> This comes as good news to us AGPH longs -- just after someone tries to discredit AGPH's efforts for Viracept. Again, if the story about Glaxo and VRTX is true, I would like to know what letter it was and get a transcript. It would make it all the more believable to others on this thread. At least it would be better than thinking that I am witnessing a lying contest.